Karyopharm Therapeutics (KPTI) Research & Development (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Research & Development came in at $27.7 million in Q4 2025, down 16.92% YoY from $33.3 million in Q4 2024, and down 9.42% on a QoQ basis from $30.5 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Research & Development (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Research & Development data on file, last reported at $27.7 million in Q4 2025.
- Quarterly Research & Development fell 16.92% year-over-year to $27.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $125.6 million (down 12.3% YoY) and the FY2025 annual result came in at $125.6 million, down 12.3% from the prior year.
- Research & Development declined to $27.7 million in Q4 2025, from $30.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $45.8 million in Q3 2021 to a low of $27.7 million in Q4 2025.
- A 5-year average of $35.9 million and a median of $35.0 million in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 30.39% in 2022, down 31.54% in 2022.
- Tracing KPTI's Research & Development over 5 years: stood at $44.0 million in 2021, then retreated by 29.7% to $30.9 million in 2022, then grew by 27.31% to $39.4 million in 2023, then dropped by 15.44% to $33.3 million in 2024, then declined by 16.92% to $27.7 million in 2025.
- The last three Research & Development figures came in at $27.7 million (Q4 2025), $30.5 million (Q3 2025), and $32.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 97.90 Mn |
| 10 | Karyopharm Therapeutics | 55.13 Mn | 55.13 Mn | 32.35 Mn | 28.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.96 Mn |
| Dec 31, 2025 | 27.67 Mn |
| Sep 30, 2025 | 30.54 Mn |
| Jun 30, 2025 | 32.79 Mn |
| Mar 31, 2025 | 34.62 Mn |
| Dec 31, 2024 | 33.30 Mn |
| Sep 30, 2024 | 36.13 Mn |
| Jun 30, 2024 | 38.37 Mn |
| Mar 31, 2024 | 35.43 Mn |
| Dec 31, 2023 | 39.38 Mn |
| Sep 30, 2023 | 35.55 Mn |
| Jun 30, 2023 | 31.48 Mn |
| Mar 31, 2023 | 32.34 Mn |
| Dec 31, 2022 | 30.93 Mn |
| Sep 30, 2022 | 31.36 Mn |
| Jun 30, 2022 | 44.31 Mn |
| Mar 31, 2022 | 42.06 Mn |
| Dec 31, 2021 | 44.00 Mn |
| Sep 30, 2021 | 45.81 Mn |
| Jun 30, 2021 | 33.98 Mn |